These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33732977)

  • 1. Roxadustat for CKD-related Anemia in Non-dialysis Patients.
    Coyne DW; Roger SD; Shin SK; Kim SG; Cadena AA; Moustafa MA; Chan TM; Besarab A; Chou W; Bradley C; Eyassu M; Leong R; Lee TT; Saikali KG; Szczech L; Yu KP
    Kidney Int Rep; 2021 Mar; 6(3):624-635. PubMed ID: 33732977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
    Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
    J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
    Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
    Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
    Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
    Larkin J; Hymes J; Britton ML; Oluwatosin Y; Nolen J; Zhu L; Silva A
    Hemodial Int; 2024 Jan; 28(1):59-71. PubMed ID: 37875459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
    Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
    Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE
    J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
    Shutov E; Sułowicz W; Esposito C; Tataradze A; Andric B; Reusch M; Valluri U; Dimkovic N
    Nephrol Dial Transplant; 2021 Aug; 36(9):1629-1639. PubMed ID: 33630072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
    Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
    Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 3b, multicenter, open-label, single-arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations.
    Fishbane S; Vishnepolsky M; Oluwatosin Y; Nolen J; Zhu L; Cooper K; Young A
    Hemodial Int; 2023 Oct; 27(4):400-410. PubMed ID: 37380364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
    Charytan C; Manllo-Karim R; Martin ER; Steer D; Bernardo M; Dua SL; Moustafa MA; Saha G; Bradley C; Eyassu M; Leong R; Saikali KG; Liu C; Szczech L; Yu KP
    Kidney Int Rep; 2021 Jul; 6(7):1829-1839. PubMed ID: 34307977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
    Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
    Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan.
    Hamano T; Yamaguchi Y; Goto K; Mizokawa S; Ito Y; Dellanna F; Barratt J; Akizawa T
    Adv Ther; 2024 Apr; 41(4):1526-1552. PubMed ID: 38363463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis.
    Chong S; Xie Q; Ma T; Xiang Q; Zhou Y; Cui Y
    Front Pharmacol; 2022; 13():967532. PubMed ID: 36188528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.